Checkpoint Therapeutics to Participate in Three September 2020 Virtual Investor Conferences

by NASDAQ Market News September 10, 2020

NASDAQ Market News
Click here to email author

Genmab Announces that Janssen has Submitted a Supplemental Biologics License Application to U.S. FDA for use of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) in Patients with Light-chain (AL) Amyloidosis

Immunoscore® to select patients in the POCHI trial, a phase II multicenter trial testing immunotherapy with chemotherapy and bevacizumab in metastatic colorectal cancer

Ads